Today, Australian Governments continue to choose CSL Biotherapies as Australia’s national plasma fractionator, and we are regulated by the Therapeutic Goods Administration, a regulator held in high regard worldwide.

Working together CSL Biotherapies and the Australian Red Cross Blood Service ensure that the blood and plasma donations made voluntarily by Australia's community continue to deliver the benefits that self-sufficiency provides – a sustainable, reliable and high quality source of plasma-derived therapies, developed to treat serious medical conditions including immunodeficiencyies, a range of haematological and neurological disorders, haemophilia, haemolytic disease of the newborn and trauma.

CSL Biotherapies also has the technology, understanding, experience and infrastructure necessary to develop and manufacture a range of specific immunoglobulins or ‘hyperimmunes’. The specific immunoglobulins made by CSL Biotherapies protect Australia's population against infection by cytomegalovirus, hepatitis B virus, zoster (chickenpox) virus and tetanus. CSL Biotherapies also manufactures Rh(D) Immunoglobulin to protect babies from haemolytic disease of the newborn. The same skills and technology that CSL Biotherapies deploys to make the specific immunoglobulins could quickly be developed to protect the Australia's population from emerging diseases.

For more information about these products, please refer to the table below.

A-Z of Australian products

A B C H I M N P R T Z

Product Name	Subcategory	Description
A
ALBUMEX^® 4	Critical Care	Used when the blood volume is low, during heart-lung bypass surgery, and in plasma exchange.
ALBUMEX^® 20	Critical Care	Used when quantity of albumin in blood is low, for resuscitation in shock, in extensive burns, respiratory distress syndrome, blood purification and plasma exchange.
B
BERINERT^®	Critical Care	Used for the treatment of acute attacks in patients with hereditary angioedema.
BIOSTATE^®	Coagulation Disorders	Used for patients with haemophilia A, in which there are reduced levels of factor VIII.
C
CMV Immunoglobulin-VF	Immune Therapy	Used to help prevent cytomegalovirus infection in specific transplant patients.
H
Hepatitis B Immunoglobulin-VF	Immune Therapy	Used to help prevent hepatitis B infection in a person who comes into contact with suspected infected material.
I
INTRAGAM^® P	Immune Therapy	Used to replace antibodies to help prevent infections and also used in the treatment of some autoimmune disorders.
M
MonoFIX^®-VF	Coagulation Disorders	Used in patients with haemophilia B, in which there are reduced levels of Factor IX.
N
Normal Immunoglobulin-VF	Immune Therapy	Used for the replacement of antibodies to help prevent infections.
P
PROTHROMBINEX^®-VF	Coagulation Disorders	Used for the prevention and treatment of bleeding in patients with reduced levels of factor IX, II or X.
R
Rh(D) Immunoglobulin-VF	Immune Therapy	Used to prevent Haemolytic Disease of the Newborn.
RHOPHYLAC^®	Immune Therapy	Used in large fetomaternal haemorrhage (FMH), or for inadvertent or emergency transfusion of Rh (D) positive blood to an Rh (D) negative female of childbearing potential.
T
Tetanus Immunoglobulin-VF IM	Immune Therapy	Used to help prevent tetanus in a person who has not recently been immunised against tetanus.
Tetanus Immunoglobulin-VF IV	Immune Therapy	Used to treat tetanus infection.
THROMBOTROL^®-VF	Critical Care	Used for the treatment of patients with conditions relating to an inherited deficiency of antithrombin III.
Z
Zoster Immunoglobulin-VF	Immune Therapy	Used to help prevent chickenpox and shingles.

CSL | Privacy | Terms of Use | Webmaster